TrumpRx.gov launches with coupons for Ozempic, Wegovy and Zepbound
The site lists cash prices well below list for three GLP-1 brands, but how the coupons interact with insurance and which pharmacies accept them has not been disclosed.
TrumpRx.gov, a federal website listing discounted cash prices for brand-name prescription drugs, went live on February 5, 2026, with coupons for 40 medicines from five manufacturers, including semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound) [1].
The White House fact sheet says the launch covers drugs from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer — the first five companies to reach "most-favored-nation," or MFN, pricing deals with the administration [1]. Under those agreements, prices shown on the site are meant to match the lowest prices paid in other developed countries [1]. Medicines from other companies that have signed MFN deals will be added "in the coming months," with no date given [1].
What the GLP-1 prices look like
The fact sheet lists these monthly figures: Ozempic falls from $1,028 to an average of $350 and as low as $199, depending on dosage strength; injectable Wegovy falls from $1,349 to an average of $350 and as low as $199; the Wegovy pill falls from $1,349 to as low as $149; and Zepbound falls from $1,088 to an average of $346 and as low as $299 [1].
Drug Topics reported more detail on the semaglutide doses: the lowest strengths, 0.25 mg and 0.5 mg, are listed at $199, and the highest strength at $499 [2]. The publication also reported that the $199 price applies for the first two months and then rises to $349 [2]. The White House fact sheet describes $199 as depending on dosage strength but does not mention a time limit [1].
Other drugs on the launch list include the fertility medicines Gonal-F, at as low as $168 per pen, Cetrotide, cut from $316 to $22.50, and Ovidrel, cut from $251 to $84 [1]. The fact sheet says patients who pay out of pocket for fertility drugs will save more than $2,000 per cycle on average [1]. The list also includes the COPD inhaler Bevespi Aerosphere, cut from $458 to $51; the asthma inhaler Airsupra, cut from $504 to $201; the eczema ointment Eucrisa, cut from $792 to $158; insulin lispro at as low as $25 a month; and Duavee, cut from $202 to $30 [1].
Drug Topics separately reported a $35 monthly cap on Novo Nordisk insulin products and a $50 monthly copay cap for Medicare beneficiaries on semaglutide and tirzepatide, along with Medicare and Medicaid coverage of obesity medications [2]. The White House fact sheet does not mention those caps or the Medicare coverage change [1].
Per the fact sheet, patients with valid prescriptions can get the savings through coupons that can be printed or downloaded to a phone, or through manufacturer channels built into the site [1]. Which pharmacies accept the coupons, whether they can be used alongside insurance, and how eligibility is checked have not been reported.
Why it matters for patients
List prices for these drugs have been in the four-figure range per month, so the figures posted on the site are far below what uninsured patients or those with high deductibles have been quoted [1]. Novo Nordisk also committed $10 billion and Eli Lilly at least $27 billion to US manufacturing, including plans to make future oral medicines domestically end to end [2].
Because the posted prices vary by dose strength, the number that applies to any one person depends on the strength prescribed [1]. If the $199 rate on semaglutide is time-limited, as Drug Topics reported, the amount paid after two months would rise to $349 [2] — but the fact sheet does not describe that limit, so the two accounts of how long the lowest rate lasts do not fully match [1][2].
What happens next
More drugs from manufacturers that have signed MFN deals are expected on the site in the coming months; no specific date has been given [1]. On January 15, 2026, President Trump called on Congress to pass what the fact sheet calls The Great Healthcare Plan, which would write the MFN savings into law; the fact sheet does not say whether that legislation has been introduced or passed [1]. The administration says it has announced 16 MFN deals with drugmakers since September 30, 2025 [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.